New vaccine aims to tackle multiple salmonella strains at once
NCT ID NCT07663032
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study tests a new quadrivalent Pan-Salmonella vaccine designed to protect against several types of Salmonella bacteria that cause typhoid and paratyphoid fevers. Healthy adults aged 18 to 45 in Africa receive either a low or full dose of the vaccine, with or without an adjuvant (alum), to see how safe it is and how well it triggers an immune response. The trial is the first step in humans for this vaccine and will monitor side effects and antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pan-Salmonella vaccine (with or without alum)
- What this could lead to
- If successful, this could lead to a vaccine that protects against multiple Salmonella strains, reducing typhoid and paratyphoid fever in Africa.
- What could go wrong
- This is an early phase 1 trial with only 196 participants, so safety and immune response are still being tested. The vaccine may not produce strong enough protection or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALMONELLA INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGBloemfontein, 9301, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.